A particularly high percentage of tumors with moderate to strong AR immunostaining was detected in sex cord-stromal tumors of the testis (93.3–100%), adenocarcinoma of the prostate (79.3–98.7%), breast neoplasms (25.0–75.5%), other gynecological tumors (0.9–100%), renal cell carcinomas (5.0–44.1%), and in urothelial carcinomas (5.4–24.2%). This evidence concerns the gene AR and prostate adenocarcinoma.